Ep 84 | CMS OPPS Drug Acquisition Cost Survey (ODACS)
In this episode, Rob and Greg are joined by guest Andy Ruskin, healthcare attorney and government payer expert from K&L Gates. They’ll be discussing the 2026 CMS OPPS Final Rule, focusing on the provi...
26 Tammi 1h 3min
Ep 83 | 340B Rebates Are on Hold
In this episode, Greg and Rob share some initial reactions around the recent judicial activity affecting HRSA's 340B rebate model. They'll discuss thoughts on the federal court ruling that halted the ...
12 Tammi 27min
Ep 82 | Recap of 340B Developments from 2025
In this episode, Greg and Rob recap key developments in the 340B space from 2025. They’ll discuss the flurry of activity in recent months related to 340B rebates, project the impact of the OBBB on DS...
22 Joulu 202545min
Ep 81 | 340B Rebate Q&A with Beacon
In this episode, Greg and Rob are joined by Katheryne Richardson of the Beacon team, to discuss frequently asked questions about the upcoming 340B rebate model. They’ll cover the differences between ...
8 Joulu 20251h 19min
Ep 80 | 340B Updates, including CMS CY26 OPPS Final Rule and Rebate Developments
In this episode, Greg and Rob catch up on some clarifications gained around the upcoming 340B rebate model, including purchasing requirements and developments with select chain retail pharmacies updat...
1 Joulu 202547min
Ep 79 | 340B Rebate Model Update
In this episode, Greg and Rob share initial reactions to the HRSA update on 340B rebate model implementation. They’ll review the communication provided by HRSA on October 30th on their website, as wel...
3 Marras 202552min
Ep 78 | Government Shutdown, Most Favored Nations Pricing and Direct-to-Consumer Pharmacy Supply Chain Discussion
In this episode, Greg and Rob chat about what the government shutdown might mean for 340B Program oversight in the short-term. They’ll also discuss a flurry of developments from manufacturers recently...
13 Loka 202533min
Ep 77 | DSH Hospital Threats
In this episode, Greg and Rob are joined by SpendMend colleague Heather Lynch, to talk about how H.R.1 (i.e. One Big Beautiful Bill Act, or OBBBA) could impact 340B covered entities in the long run. T...
29 Syys 202550min
